|

Pegylated interferon α-2b Clinical Trials

1 actively recruiting trial

Also known as: PEG IFNα-2b

Pipeline

Phase 2: 1

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Polycythemia Vera1
  • Cancer1

Other1 trial

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.